vTv Therapeutics Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
vTv Therapeutics reported Q2 2026 cash position of $86.6M (down $2.3M from Dec 31, 2025), with Q2 net loss of $13.1M ($1.05/share) vs. $6.0M loss in Q2 2025. R&D expenses doubled to $8.8M from $4.1M YoY due to Phase 3 CATT1 trial advancement. The company expects Phase 3 CATT1 enrollment completion in Q3 2026 and sufficient cash runway through anticipated topline data readout; a Phase 2a Hybrid CATT1 trial is planned to initiate before year-end 2026.
Why this rating
Cash burn accelerating ($13.1M/quarter) against modest runway (~$86.6M); Phase 3 progress is positive but dependent on trial outcomes. Moderate relative to company scale.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.